2 hours ago
1
Reuben Gregg Brewer, The Motley Fool
Sat, April 25, 2026 astatine 9:35 AM CDT 4 min read
Shares of Pfizer (NYSE: PFE) person fallen 55% from their precocious 2021 high. That diminution highlights a worldly alteration successful Wall Street's presumption of the pharmaceutical giant. And it has pushed the dividend output up to a lofty 6.3%. Is the dividend really sustainable? Here's what you request to know.
There's really thing antithetic going connected with Pfizer's pharmaceutical business. The manufacture is highly competitive, capital-intensive, and driven by innovation. Unfortunately, probe and improvement outcomes aren't predictable. Sometimes things don't enactment retired arsenic good arsenic planned.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
That's 1 large sound against the institution today, fixed that its internally developed GLP-1 weight-loss cause campaigner had to beryllium abandoned. GLP-1 drugs are the blistery taxable connected Wall Street, and Pfizer isn't adjacent successful the crippled yet.
The antagonistic capitalist sentiment surrounding Pfizer's GLP-1 concern added to the vaccine issues the institution was already facing. Part of a banal terms rally up until precocious 2021 was driven by investors excited by the company's COVID vaccine opportunity. While vaccine income were precise beardown for a abbreviated period, the semipermanent accidental proved little robust than expected, and they haven't been a beardown constituent for Pfizer.
There are precise bully reasons for investors to beryllium downbeat astir Pfizer close now. However, the heavy drawdown successful the banal is truly a premix of existent pessimism pursuing what present appears to beryllium excessively overmuch enthusiasm. Pfizer, with a $155 cardinal marketplace cap, is inactive a ample and innovative healthcare giant.
As noted, you can't foretell probe outcomes. But fixed Pfizer's agelong and palmy history, it seems highly apt that it volition yet make caller and innovative drugs. Notably, it rapidly shifted gears successful the GLP-1 space, buying a institution with an charismatic GLP-1 cause campaigner and partnering with different institution to administer its GLP-1 cause if it gets approved. It is besides pushing guardant with oncology and migraine drugs, since weight-loss is lone 1 of the galore areas connected which the institution is focused.
Meanwhile, the institution is being precise wide astir the dividend. Pfizer's full-year 2025 net telephone presumption includes a forward-looking descent that prominently states a semipermanent extremity of maintaining the dividend.
English (CA) · 
English (US) · 
Spanish (MX) ·